<DOC>
	<DOCNO>NCT01419327</DOCNO>
	<brief_summary>This study regulatory post marketing surveillance Japan , local prospective observational study patient hemodialysis receive Fosrenol hyperphosphatemia . The objective study ass safety efficacy use Fosrenol clinical practice . A total 3,000 patient recruit follow 5 year .</brief_summary>
	<brief_title>Fosrenol Post-marketing Surveillance Hemodialysis Japan</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients undergoing hemodialysis receive Fosrenol hyperphosphatemia Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Fosrenol</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>